Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Jaksche

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Journal of Virology|November 1, 1994
Scanning mutagenesis of the arginine-rich region of the human immunodeficiency virus type 1 Rev trans activatorM Hammerschmid, D Palmeri, M Ruhl, et al.
Der Orthopade|January 30, 2004
[Conventional and semi-open kyphoplasty]B M Boszczyk, M Bierschneider, S Hauck, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 1998
Interaction of the HIV-1 rev cofactor eukaryotic initiation factor 5A with ribosomal protein L5O Schatz, M Oft, C Dascher, et al.
Biochemistry|October 5, 1993
Biochemical characterization of binding of multiple HIV-1 Rev monomeric proteins to the Rev responsive elementT J Daly, R C Doten, P Rennert, et al.
The Journal of Cell Biology|December 1, 1993
Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activationM Ruhl, M Himmelspach, G M Bahr, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1994
Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analogB Rosenwirth, A Billich, R Datema, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 1987
Anti-idiotype immunization of cancer patients: modulation of the immune responseD Herlyn, M Wettendorff, E Schmoll, et al.
Science (New York, N.Y.)|March 29, 1996
Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5AD Bevec, H Jaksche, M Oft, et al.
Neurochirurgia|May 1, 1985
Clinical experience with nimodipine in the prophylaxis of neurological deficits after subarachnoid hemorrhageE Kazner, C Sprung, D Adelt, et al.
Neurochirurgia|May 1, 1985
Nimodipine treatment of ischemic neurological deficits due to cerebral vasospasm after subarachnoid hemorrhage. Clinical results of a multicenter studyW T Koos, A Perneczky, L M Auer, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Journal of Virology|November 1, 1994
Scanning mutagenesis of the arginine-rich region of the human immunodeficiency virus type 1 Rev trans activatorM Hammerschmid, D Palmeri, M Ruhl, et al.
Der Orthopade|January 30, 2004
[Conventional and semi-open kyphoplasty]B M Boszczyk, M Bierschneider, S Hauck, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 1998
Interaction of the HIV-1 rev cofactor eukaryotic initiation factor 5A with ribosomal protein L5O Schatz, M Oft, C Dascher, et al.
Biochemistry|October 5, 1993
Biochemical characterization of binding of multiple HIV-1 Rev monomeric proteins to the Rev responsive elementT J Daly, R C Doten, P Rennert, et al.
The Journal of Cell Biology|December 1, 1993
Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activationM Ruhl, M Himmelspach, G M Bahr, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1994
Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analogB Rosenwirth, A Billich, R Datema, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 1987
Anti-idiotype immunization of cancer patients: modulation of the immune responseD Herlyn, M Wettendorff, E Schmoll, et al.
Science (New York, N.Y.)|March 29, 1996
Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5AD Bevec, H Jaksche, M Oft, et al.
Neurochirurgia|May 1, 1985
Clinical experience with nimodipine in the prophylaxis of neurological deficits after subarachnoid hemorrhageE Kazner, C Sprung, D Adelt, et al.
Neurochirurgia|May 1, 1985
Nimodipine treatment of ischemic neurological deficits due to cerebral vasospasm after subarachnoid hemorrhage. Clinical results of a multicenter studyW T Koos, A Perneczky, L M Auer, et al.
Pageof 5